Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
COMPARING CREAMS
Investigators with Dermatology Associates, St. Luke's-Roosevelt Hospital, N.Y., conducted two 8-week, multi-center, randomized, investigator-blind studies to compare the efficacy and safety of a hydrophilic cream formulation containing tretinoin 0.05 percent, hydroquinne 4.0 percent and fluocinolone acetonide 0.01 percent (RA+HQ+FA) with the dual-combination agents tretinoin hydroquinone, tretinoin plus fluocinolone acetonide, and hydroquinone plus fluocinolone acetonide.
Related Videos
Related Content
